NASDAQ:STRO
Sutro Biopharma Inc. Stock News
$4.15
-0.200 (-4.60%)
At Close: May 10, 2024
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Lags Revenue Estimates
09:28am, Thursday, 18'th Mar 2021
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -164.29% and -32.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the s
Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones
07:00am, Thursday, 18'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 18, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of
Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
01:38pm, Monday, 08'th Mar 2021
Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro: Leading Cell Free Protein Synthesis Company With Promising Early Data
10:00am, Wednesday, 06'th Jan 2021
Sutro is a leader in CFPS and has major collaborations to prove it. Its early data is a lethal late line cancer is very promising.
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering
09:10pm, Tuesday, 08'th Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 8, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of pre
Why iBio, Sutro And Cantel Medical Are Moving Today
12:41pm, Tuesday, 08'th Dec 2020
iBio (NYSE: IBIO) shares are trading lower on Tuesday after the company announced a common stock offering. iBio's main area of business is plant-based protein expression technologies for vaccines and
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of pre
Why Sutro Biopharma Blasted 33% Higher on Friday
06:22pm, Friday, 04'th Dec 2020
One of the company's pipeline treatments shows encouraging results in ovarian cancer patients.
Why BioCryst, Moderna And More Are Moving Today
12:59pm, Friday, 04'th Dec 2020
Sutro Biopharma (NASDAQ: STRO) shares are trading higher on Friday after the company announced interim data on its STRO-002 Phase 1 dose-escalation study for patients with ovarian cancer. Sutro Biopha
Sutro Biopharma: 7 Things for STRO Stock Investors to Know About the Biotech Company
11:46am, Friday, 04'th Dec 2020
Sutro Biopharma (STRO) is on the rise Friday with heavy trading of STRO stock despite the company not announcing anything new today. The post Sutro Biopharma: 7 Things for STRO Stock Investors to Know
Sutro Bio's Ovarian Cancer Treatment Ready for the Next Level
09:42am, Friday, 04'th Dec 2020
Sutro Biopharma Inc. (NASDAQ: STRO) made a huge gain to close out the week after the firm provided an update from its ongoing dose-escalation in its ovarian cancer trial.
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
04:30pm, Thursday, 03'rd Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of pre
